• Martin is Professor of Cardiometabolic Medicine at the University of Manchester and Honorary Consultant Physician at the Diabetes, Endocrinology and Metabolism Centre, Manchester Royal Infirmary. He is Deputy Chief Scientist at UK Biobank (June 2024 onwards). He is PI of the SURMOUNT-REAL UK trial. His main research interest is the pathogenesis of cardiometabolic diseases such as heart disease, obesity and diabetes and digital interventions in diabetes. He has had several roles with Diabetes UK including: member, Science and Research Advisory Committee (2018 onwards); and Chair, Diabetes Research Steering Group 6 (diabetes-related complications). He is a past Chair of Diabetes UK's Professional Conference Organising Committee. He has been clinical lead physician for the islet cell transplantation service and co-lead for the diabetes-renal service at Manchester University NHS Foundation Trust.

• Martin received his undergraduate education at Edinburgh University Medical School. He was trained in Diabetes and Endocrinology in Newcastle-upon-Tyne, UK, where he received a Doctorate of Medicine degree for research work in the cardiovascular complications of diabetes. Between 2000 and 2002 was a Research Fellow in Cardiology and Endocrinology at the Lahey Clinic, MA, USA where he worked with the Framingham Heart Study team. He was a Consultant Physician in General Medicine, Diabetes and Endocrinology in Chester, UK, between 2002 and 2006; and then moved to Manchester Royal Infirmary from 2006 until 2009, where he was a Consultant Physician in General Medicine and Diabetes.
• He is currently Professor of Cardiometabolic Medicine at the University of Manchester. Prior to this, he held a HEFCE-funded Clinical Senior Lecturer post at the University of Manchester from 2009. His research is focussed on the pathogenesis of cardiometabolic disease and covers a range of areas including: sleep/circadian disruption; vascular stiffness; cardiovascular disease in diabetes; digital interventions in diabetes; and islet and pancreas transplantation. He has secured £60M+ research income. He has current research funding from National Institute for Health Research (NIHR), Innovate UK, Diabetes UK and NIHR Manchester Biomedical Research Centre. He is also a named investigator in the successful NIHR Manchester Biomedical Research Centre application in 2022 (CVD theme).
• Martin has publications in leading journals focusing on the pathogenesis of cardiometabolic disease including several with the Framingham Heart Study and more recently with teams working with UK Biobank data. He leads several research collaborations with groups in the UK, Europe and the USA. He served as an Associate Editor for Diabetic Medicine between 2004 and 2010 (cardiovascular manuscripts), for Diabetologia between 2014 and Dec 2017 (cardiovascular manuscripts), and for Current Cardiovascular Risk Reports between 2012 and 2016. He served on the Advisory Board for Diabetologia 2017-2021.

• MB ChB, 1985, Edinburgh University Medical School
• DGM, 1991, Royal College of Physicians, Glasgow
• MRCP (UK) 1991, Royal College of Physicians, UK
• Dip Med Sci, 1994, University of Newcastle upon Tyne
• MD, 2003, University of Newcastle upon Tyne
• FRCP, 2005, Royal College of Physicians, Edinburgh
• FHEA, 2013, The Higher Education Academy, UK

• UK Biobank: his work with the scientific team focusses on developing this world-leading resource for researchers.
• SURMOUNT-REAL UK: this 5-year real-world trial will assess the health and economic imacts of the obesity drug, tirzepatide.
• Metabolic predictors of cardiometabolic disease: his epidemiology work largely focuses on understanding mechanisms of disease using data from UK Biobank, the Clinical Practice Research Datalink (CPRD), the European Male Ageing Study (EMAS), islet and pancreas transplant registries and locally generated data.
• Sleep/circadian disruption: he leads an international research group exploring causal relationships between sleep/circadian rhythms and cardiometabolic and other diseases using UK Biobank data.
• Vascular stiffness: he leads a group exploring the pathogenesis of vascular stiffness using UK Biobank data. He is co-lead of a UK Biobank Cardiometabolic Peripheral Arterial Disease (PAD) working group. 
• Cardiovascular disease in diabetes: he leads and supports projects investigating the links between diabetes and cardiovascular disease using primary care and registry data.

Manchester

• Sleep/chronotype - Manchester Centre for Biological Timing: Prof David Bechtold, Dr Hannah Durrington, Dr John Blaikley, Prof Rob Lucas.
• Diabetes and cardiovascular risk: Prof Darren Ashcroft, Dr Alison Wright, Dr Matthew Carr, Prof Evan Kontapantelis.

Other UK

• Sleep/circadian rhythms: Prof Debbie Lawlor, Prof Jack Bowden, Prof Simon Kyle, Prof Mike Weedon, Dr Andy Wood, Dr Rebecca Richmond, Prof David Ray

Europe

• Sleep/chronotype: Dr Kai Spiegelhalder.
• The European Male Ageing Study: several PIs: http://www.emas.man.ac.uk

USA

• Sleep/circadian rhythms: Prof Richa Saxena, Dr Jackie Lane, Prof Susan Redline, Dr Hassan Dashti and Prof Frank Scheer (Harvard Medical School)

• Epidemiology and statistics
• Vascular biology
• Integtative genomics

• Diabetes UK: Chair, Professional Conference Organising Committee; member, Science and Research Advisory Committee (2018 -2025); Chair, Diabetes Research Steering Group 6 (diabetes-related complications; 2019-2025)
• European Association for the Study of Diabetes
• American Heart Association
• Advisory Committee on Clinical Excellence Awards, regional sub-committee member (2018-2021)

• Undergraduate: he leads a clinical teaching firm and teaches 3rd-year medical students on a weekly basis.
• Postgraduate: he is regularly invited to lecture on aspects of diabetes including CVD risk and islet cell transplantation.